1799.TWO Easywell Biomedicals Inc.
- Market cap
- TWD 3.12B
- P/E
- -
- P/B
- 4.46x
- ROE
- 2.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 1799.TWO undervalued?
Graham numberThe Graham number of Easywell Biomedicals Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Easywell Biomedicals Inc. fundamental analysis
No fundamental analysis for Easywell Biomedicals Inc. yet.
Easywell Biomedicals Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Easywell Biomedicals Inc.
Easywell Biomedicals, Inc., together with its subsidiaries, develops, manufactures, and sells generic pharmaceutical ingredients and products in America, China, and Taiwan. The company develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for the treatment of breast cancer in PMS women; TLX-007 and TLX-004, which are anti-depressants; TLX-008 for the prevention of pneumocystis pneumonia; TLX-012 for the treatment of epilepsy; TLX-0…
Full company profileEasywell Biomedicals Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Easywell Biomedicals Inc. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 360M | 268M | 197M | 179M | 272M | 540M | 597M | 927M |
| Gross Profit | 35.5M | 84.0M | 50.4M | 76.3M | 171M | 299M | 280M | 443M |
| Operating Income | -216M | -167M | -154M | -151M | -151M | -69.8M | -69.8M | 33.8M |
| EBITDA | -162M | -85.8M | -82.7M | -84.5M | -85.5M | 12.8M | 38.4M | 146M |
| Net Income | -272M | -173M | -150M | -161M | -145M | -97.5M | -73.1M | 15.9M |
| EPS | -3.09 | -1.84 | -1.44 | -1.39 | -1.25 | -0.80 | -0.59 | 0.13 |
| Balance Sheet | ||||||||
| Total Assets | 1.17B | 1.11B | 1.26B | 1.17B | 1.21B | 1.51B | 1.29B | 1.29B |
| Total Liabilities | 477M | 344M | 352M | 403M | 590M | 766M | 590M | 568M |
| Shareholders' Equity | 677M | 704M | 874M | 738M | 613M | 719M | 691M | 709M |
| Cash & Short-term Investments | 237M | 231M | 439M | 340M | 348M | 326M | 281M | 361M |
| Total Debt | - | 316M | 325M | 350M | 386M | - | - | - |
| Cash Flow | ||||||||
| Operating Cash Flow | -171M | -158M | -128M | -53.5M | -151M | -159M | 125M | 215M |
| Capital Expenditure | 21.7M | 17.2M | 7.71M | 7.49M | 18.5M | 12.8M | 15.4M | 8.74M |
| Free Cash Flow | -193M | -175M | -136M | -61.0M | -170M | -172M | 109M | 207M |
| Ratios | ||||||||
| ROE | -40.1% | -24.6% | -17.2% | -21.8% | -23.6% | -13.6% | -10.6% | 2.2% |
| ROA | -23.2% | -15.7% | -11.9% | -13.7% | -11.9% | -6.5% | -5.7% | 1.2% |
| Net Profit Margin | -75.5% | -64.8% | -76.2% | -90.0% | -53.3% | -18.0% | -12.2% | 1.7% |
| Debt to Equity | - | 0.45x | 0.37x | 0.47x | 0.63x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Easywell Biomedicals Inc. dividends
Easywell Biomedicals Inc. has not paid dividends in the last 7 fiscal years.
Last stock split: 700:1000 on Sep 30, 2022.
Who owns Easywell Biomedicals Inc.
- Insiders 38.82%
- Institutions 11.48%
- Public & others 49.70%
- Shares outstanding 125M
- Free float 1.25M
Easywell Biomedicals Inc. company profile
- Company name
- Easywell Biomedicals Inc.
- Ticker
- 1799.TWO
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- December
- Address
- No.10, Yanfa 2nd Rd., Hsinchu City, Taiwan, 30076
- Phone
- 886 3 666 9596
- Website
- easywellbio.com
About Easywell Biomedicals Inc.
Easywell Biomedicals, Inc., together with its subsidiaries, develops, manufactures, and sells generic pharmaceutical ingredients and products in America, China, and Taiwan. The company develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for the treatment of breast cancer in PMS women; TLX-007 and TLX-004, which are anti-depressants; TLX-008 for the prevention of pneumocystis pneumonia; TLX-012 for the treatment of epilepsy; TLX-017 for the treatment of chronic angina; and TLX-011 for the treatment of inflammatory lesions of rosacea. It is also developing TLX-015, a medicine for the prevention and treatment of postpartum hemorrhage; TLX-018, a hemorrhage treatment drug; TLX-030, a medication for adrenal insufficiency treatment; TLX-047, a systemic corticosteroid; HH-001, a sacubitril/valsartan sodium tablet; TLX-024, a liquid oral anticonvulsant; TLX-034, an endocrine drug; TWB-201, a Parkinson patch; TLX-501, a urinary medicine; and TLX-502, a pneumonia medicine. In addition, the company offers health food and products; and over-the-counter drugs. The company was formerly known as Actherm Inc. and changed its name to Easywell Biomedicals, Inc. in July 2015. Easywell Biomedicals, Inc. was incorporated in 1998 and is headquartered in Hsinchu City, Taiwan.
Easywell Biomedicals Inc. management
6- Mr. Jian-Lun MaVice President
- Mr. James Aiping Lee Ph.D.CEO, Manager & Representative Director
- Hsueh-Chun WuAccounting Supervisor
- Dr. Yu-Hsing Tu Ph.D.Chief Science Officer
- Dr. She Bin-Ru Ph.D.Chief Technical Officer of Regenerative Medicine Division
- Yueh-Ning LeeVice President